At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
Glucagon +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Randomized, Placebo (Saline)-Controlled, Balanced, 3-treatment Regimen Crossover Study Comparing the Effects of Prolonged (13 h) Hyperglucagonemia With Those of Acute (3 hr) Hyperglucagonemia on Energy Expenditure and Endogenous Glucose Protection (EGP).
AdventHealth Translational Research Institute·interventional·Posted Sep 11, 2014·Updated Apr 26, 2018
In Brief
A Phase 1 clinical trial evaluating Glucagon, Octreotide, and 2 other interventions for Hyperglucagonemia and Obesity. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The purpose of this study is to collect data to help researchers better understand the effects of glucagon on the amount of calories burned.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperglucagonemia, Obesity
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedSep 2014
Primary CompletionJun 2015
Study CompletionJun 2016
TodayJul 2026
First PostedSep 11, 2014
Enrollment StartSep 1, 2014
Primary CompletionJun 1, 2015
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.8 years ago
Interventions
Glucagondrug
Octreotidedrug
Placebobehavioral
Insulindrug